The relevance of EMT in resistance to EGFR inhibition in the clinical setting was validated by the demonstration that a 76-gene EMT signature developed in vitro with NSCLC lines could then predict response to erlotinib in patients with EGFR/KRAS wild type tumors [36]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.